中国经济网北京8月7日讯（记者 何潇） 今年前7个月，全市场650只（各类份额分开计算，下同）有可 比业绩的QDII基金中，共有600只基金净值上涨，占比92.31%；有49只基金净值下跌；其余1只基金净 值持平。 以工银新经济混合美元、工银新经济混合人民币为例，截至二季度末，该基金的前十大重仓股为科伦博 泰生、信达生物、三生制药、海思科（002653）、药明康德（603259）、恒瑞医药（600276）、再鼎医 药、百济神州、先声药业、翰森制药。目前由基金经理赵蓓管理。赵蓓2010年加入工银瑞信，现任研究 部副总监、医疗保健研究团队负责人。 跌幅榜上，前7个月垫底QDII基金的主要为跟踪富时沙特阿拉伯指数的的产品。此外，一些跟踪标普 500医疗保健等权重指数、标普生物科技精选行业指数的QDII基金以及原油、油气类基金也表现欠佳。 汇添富香港优势精选混合A/C在今年二季度持续聚焦在创新药、优秀设备耗材龙头方向。截至二季度末 其前十大重仓股分别为映恩生物、科伦博泰生、信达生物、和黄医药、康诺亚、三生制药、诺诚健华、 石药集团、康方生物、荣昌生物。 该基金的现任基金经理为张韡。张韡曾任东方证券医药助理研究员，汇添 ...

Group 1 - The core viewpoint of the news is that multiple QDII funds, including the Bosera Nasdaq 100 ETF, are implementing subscription restrictions to protect the interests of existing fund holders and manage net asset value volatility [1][2][3] - As of August 3, 41 out of 676 QDII funds are in a suspended subscription state, and 349 funds have restricted large subscriptions, indicating that 57.69% of QDII funds are subject to some form of subscription limitation [3][4] - Several QDII funds have reported significant performance gains, with some achieving over 90% returns year-to-date, which has led to increased inflows and subsequent subscription restrictions [4][5] Group 2 - The recent approval of new QDII investment quotas aims to meet the reasonable demand for overseas investments, with 60 fund managers and securities firms receiving a total of $21.2 billion in new quotas [5] - Industry experts suggest that the strong performance of QDII funds focused on Hong Kong stocks and innovative pharmaceuticals reflects investor preference for valuation recovery and growth opportunities [5] - Future investment opportunities may arise from global technology leaders and high-quality assets in emerging markets, as well as the overseas expansion of competitive Chinese enterprises [5]